Skip to content

MapLight Therapeutics, Inc. MPLT Operating Lease Right-of-Use Assets in Other Assets

Operating Lease Right-of-Use Assets in Other Assets at other companies

Neurocrine Biosciences logo
Neurocrine BiosciencesNBIX
Acadia Pharmaceuticals logo
Acadia PharmaceuticalsACAD
MeiraGTx Holdings plc logo
MeiraGTx Holdings plcMGTX
Xenon Pharmaceuticals logo
Xenon PharmaceuticalsXENE
Taysha Gene Therapies, Inc. logo
Taysha Gene Therapies, Inc.TSHA
Catalyst Pharmaceutical logo
Catalyst PharmaceuticalCPRX

Other financials

Income statement

See full
Operating income-$64.5M-174%
Net income-$60.7M-172%
EPS (diluted)-$1.34+95.4%

Balance sheet

See full
Cash & equivalents$55.7M
Total debt$5.6M
Total equity$399.8M+285%
Total assets$418.8M

Cash flow

See full
Operating cash flow-$51.2M-100%
CapEx$24.0K
Free cash flow-$51.2M

Valuation

See full
Market cap$1.39B
Enterprise value$1.34B

Returns & leverage

See full
Return on equity-216.8%
Debt / equity
Current ratio22.9×

Where this comes from

Reported directly by MapLight Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:OperatingLeaseRightOfUseAsset.

The official record: MapLight Therapeutics, Inc. ’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →

Ask your AI about MapLight Therapeutics, Inc. 's operating lease right-of-use assets in other assets.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is MapLight Therapeutics, Inc. 's operating lease right-of-use assets in other assets?
MapLight Therapeutics, Inc. (MPLT) reported operating lease right-of-use assets in other assets of $5.26M in Q1 2026.